Glucagon-Like Peptide-1 Receptor Agonists and Fragility Fracture Risk in Type 2 Diabetes
Orthopaedic surgeons increasingly manage fragility fractures in an aging population on GLP-1 receptor agonists, and this large observational signal raises the question of whether these drugs affect bone health differently than assumed.